Drugs / JZP-258
JZP-258
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT03533114 | Nov 2018 → Jun 2020 | idiopathic hypersomnia | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03030599 | Mar 2017 → Jan 2019 | narcolepsy-cataplexy syndrome | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT05875974 | Jul 2023 → Mar 2025 | idiopathic hypersomnia, narcolepsy | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT05869773 | Jun 2023 → Feb 2025 | narcolepsy | Jazz Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT04794491 | Mar 2021 → Nov 2022 | narcolepsy | Jazz Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JZP258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05875974 ↗ |
| Known as | low-sodium oxybate | “Using data from a phase 3 trial of low-sodium oxybate in adults with idiopathic hypersomnia (NCT03533114), IHSS scores were psychometrically evaluated at Baseline, Weeks 1 and...” PMID 42382222 ↗ Jun 2026 |
| Known as | lower-sodium oxybate | “Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.” PMID 34942138 ↗ Jan 2022 |
| Known as | XYWAV | “Participants will self-administer an oral dose of JZP258 (XYWAV) as per label and titrate to an optimal dosage for each participant.” NCT05875974 ↗ |
| Route | Oral | “JZP-258 oral solution” NCT03030599 ↗ |